Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SG1408
- Development stage
- Phase 1
- Lead developer
- Shangjian Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SG1408 is a humanized monoclonal antibody targeting B7-H3 (CD276), an immune checkpoint molecule that is highly expressed in various solid tumors and plays a role in tumor immune evasion. Developed by Sino-Health (Hangzhou) Biopharmaceutical, SG1408 is designed to bind to B7-H3 on tumor cells, thereby inhibiting its immunosuppressive function and potentially inducing antibody-dependent cellular cytotoxicity (ADCC) to eliminate cancer cells. The drug is currently being investigated in a Phase I clinical trial in China for the treatment of advanced malignant solid tumors in patients who have failed standard systemic therapies.
02
Targets
Beyond the preview
Go deeper on SG1408.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SG1408.